Zenas BioPharma

ZBIOPhase 3

Zenas BioPharma is a global biopharmaceutical company with a mission to become a leader in autoimmune disease therapies, enabling patients to 'reimagine life.' Led by a veteran team with a proven track record, the company is advancing a pipeline anchored by two late-stage investigational drugs with broad potential across multiple autoimmune indications. Their strategy combines internal development with strategic partnerships and is guided by a set of core values emphasizing transparency, urgency, and innovation.

Market Cap

$1.2B

Focus

AntibodiesBiologics

ZBIO · Stock Price

USD 22.30+4.15 (+22.87%)

Historical price data

AI Company Overview

Technology Platform

Focus on developing and in-licensing differentiated therapeutic candidates with validated mechanisms for autoimmune diseases, including bifunctional antibodies and highly selective kinase inhibitors.

Pipeline Snapshot

9 drugs in pipeline, 3 in Phase 3

Drug	Indication	Stage
Obexelimab + Obexelimab	Warm Autoimmune Hemolytic Anemia	Phase 3
Orelabrutinib + Placebo	Secondary Progressive Multiple Sclerosis	Phase 3
Orelabrutinib + Placebo	Multiple Sclerosis (MS) Primary Progressive	Phase 3
Obexelimab + Placebo	Systemic Lupus Erythematosus	Phase 2
Obexelimab + Placebo	Relapsing Multiple Sclerosis	Phase 2

Funding History

Total raised: $318M

Series B$200MEnavate SciencesDec 15, 2023

Series A$118MEnavate SciencesJan 15, 2022

Opportunities

The large and growing autoimmune disease market presents a significant opportunity for differentiated therapies.

Positive Phase 3 data for obexelimab or orelabrutinib could lead to regulatory approvals across multiple indications, driving revenue growth.

The company's strategy also includes forming strategic partnerships to accelerate development and expand commercial reach.

Risk Factors

Key risks include clinical trial failures, regulatory setbacks, intense competition from established and emerging therapies, and dependence on raising additional capital as a pre-revenue company.

The company's value is highly concentrated in two lead candidates, amplifying the impact of any negative results.

Competitive Landscape

Zenas competes in the crowded autoimmune space against large pharma companies with dominant products and other biotechs. Its differentiation relies on the novel mechanisms of its candidates—obexelimab's non-depleting B cell modulation and orelabrutinib's high selectivity—which aim to offer improved efficacy and safety profiles compared to existing broad immunosuppressants and less selective BTK inhibitors.

Publications

Pipeline